Department of Pharmaceutical Biology, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
Department of Biotechnology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia.
Int J Mol Sci. 2021 Dec 16;22(24):13495. doi: 10.3390/ijms222413495.
Cathepsin X is a lysosomal peptidase that is involved in tumour progression and represents a potential target for therapeutic interventions. In addition, it regulates important functions of immune cells and is implicated in the modulation of tumour cell-immune cell crosstalk. Selective cathepsin X inhibitors have been proposed as prospective antitumour agents to prevent cancer progression; however, their impact on the antitumour immune response has been overlooked. Previous studies indicate that the migration and adhesion of T cells and dendritic cells are affected by diminished cathepsin X activity. Meanwhile, the influence of cathepsin X inhibition on natural killer (NK) cell function has not yet been explored. Here, we examined the localization patterns of cathepsin X and the role of its inhibitors on the cytotoxicity of cell line NK-92, which is used for adoptive cellular immunotherapy in cancer patients. NK-92 cells depend on lymphocyte function-associated antigen 1 (LFA-1) to form stable immunoconjugates with target cells, providing, in this way, optimal cytotoxicity. Since LFA-1 is a substrate for cathepsin X activity in other types of cells, we hypothesized that cathepsin X could disturb the formation of NK-92 immunoconjugates. Thus, we employed cathepsin X reversible and irreversible inhibitors and evaluated their effects on the NK-92 cell interactions with target cells and on the NK-92 cell cytotoxicity. We show that cathepsin X inhibition does not impair stable conjugate formation or the lytic activity of NK-92 cells. Similarly, the conjugate formation between Jurkat T cells and target cells was not affected by cathepsin X activity. Unlike in previous migration and adhesion studies on T cells, in NK-92 cells cathepsin X was not co-localized with LFA-1 at the plasma membrane but was, rather, redistributed to the cytotoxic granules and secreted during degranulation.
组织蛋白酶 X 是一种溶酶体肽酶,参与肿瘤进展,是治疗干预的潜在靶点。此外,它调节免疫细胞的重要功能,并参与肿瘤细胞-免疫细胞串扰的调节。选择性组织蛋白酶 X 抑制剂已被提议作为预防癌症进展的潜在抗肿瘤药物;然而,它们对抗肿瘤免疫反应的影响尚未被忽视。先前的研究表明,T 细胞和树突状细胞的迁移和黏附受到组织蛋白酶 X 活性降低的影响。同时,组织蛋白酶 X 抑制对自然杀伤 (NK) 细胞功能的影响尚未被探索。在这里,我们研究了组织蛋白酶 X 的定位模式及其抑制剂对用于癌症患者过继细胞免疫治疗的 NK-92 细胞系细胞毒性的作用。NK-92 细胞依赖淋巴细胞功能相关抗原 1 (LFA-1) 与靶细胞形成稳定的免疫复合物,从而提供最佳的细胞毒性。由于 LFA-1 是其他类型细胞中组织蛋白酶 X 活性的底物,我们假设组织蛋白酶 X 可能会干扰 NK-92 免疫复合物的形成。因此,我们使用了组织蛋白酶 X 可逆和不可逆抑制剂,并评估了它们对 NK-92 细胞与靶细胞相互作用以及 NK-92 细胞细胞毒性的影响。我们表明,组织蛋白酶 X 抑制不会损害稳定的共轭形成或 NK-92 细胞的裂解活性。同样,Jurkat T 细胞与靶细胞之间的共轭形成不受组织蛋白酶 X 活性的影响。与 T 细胞的先前迁移和黏附研究不同,在 NK-92 细胞中,组织蛋白酶 X 不在质膜上与 LFA-1 共定位,而是重新分布到细胞毒性颗粒中,并在脱颗粒时分泌。